The size of the Asia Pacific Cancer Metabolism Based Therapeutics market is predicted to register a promising CAGR between 2021 to 2026.
The hike in this market is driven by several factors some of them include an increase in the number of people who are diagnosed with cancer every year, smoking tobacco, exposing the body to different types of radiations, heredity, chemicals. Introducing new ways of treating cancers also increasing the market share. The high cost of treatment may drag back the market value in some of the developing countries. Around 3% of the cancer cases and 7% of cancer-related deaths in the U.S. are attributed to pancreatic cancer.
The market is segmented by Therapy, Drug type, and Indication. By therapy, the market is categorized into Biological drug therapies and Targeted drug therapies. By drug type, the market is further divided into CPI-613, Enasidenib, others. CPI-613 was introduced recently in 2018 which is considered as the best drug to treat pancreatic cancer. Enasidenib also got its importance in treating pancreatic cancer. According to a report from American Cancer Society in 2018, 53 thousand people were diagnosed with pancreatic cancer and around 43 thousand of them are experiencing a threat to their lives. By Indication, the market is segregated into Melanoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Metastatic Renal Cell Carcinoma, and others. Around twenty one thousand cases of Acute Myeloid Leukemia attacks were reported by American Cancer Society in 2018, out of which 50% are experiencing the terminal stage. Many non-profit organizations came into the picture to help people and increased awareness about symptoms and treatment process of pancreatic cancer which is helping the market to increase its size.
By geography, the market is segmented into India, China, Japan, South Korea, and others. As there are increasing cases of cancer every year in developing countries like India and China, the potential for market expansion is expected to be high in these countries.
Some of the prime manufacturers in the Asia-Pacific Cancer Metabolism Based Therapeutics are AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapy
5.1.1 Introduction
5.1.2 Biological Drug Therapies
5.1.3 Targeted Drug Therapies
5.1.4 Y-o-Y Growth Analysis, By Therapy
5.1.5 Market Attractiveness Analysis, By Therapy
5.1.6 Market Share Analysis, By Therapy
5.2 Drug Type
5.2.1 Introduction
5.2.2 Enasidenib
5.2.3 CPI-613
5.2.4 Other Drugs
5.2.5 Y-o-Y Growth Analysis, By Drug Type
5.2.6 Market Attractiveness Analysis, By Drug Type
5.2.7 Market Share Analysis, By Drug Type
5.3 Indication
5.3.1 Introduction
5.3.2 Melanoma
5.3.3 Myelodyspalstic Syndrome (MDS)
5.3.4 Acute Myeloid Leukemia (AML)
5.3.5 Metastatic Renal Cell Carcinoma
5.3.6 Others
5.3.7 Y-o-Y Growth Analysis, By Indication
5.3.8 Market Attractiveness Analysis, By Indication
5.3.9 Market Share Analysis, By Indication
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapy
6.1.3.3 By Drug Type
6.1.3.4 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapy
6.1.4.3 By Drug Type
6.1.4.4 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Therapy
6.1.5.3 By Drug Type
6.1.5.4 By Indication
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 AstraZeneca
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis
8.3 Celgene
8.4 Rafael Pharmaceuticals
8.5 Cornerstone Pharmaceuticals
8.6 Polaris Group
8.7 Agios Pharmaceuticals
8.8 Taiho Pharmaceuticals
8.9 3-V Biosciences
8.10 Calithera Biosciences
8.11 BERG Health
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
